A case of basal cell carcinoma of the nose successfully treated with 5% imiquimod cream

Jun Ha Park, Eul Sang Hwang, Sang Baik Kim, Hyo Hyun Ahn, Il-Hwan Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Basal cell carcinoma is the most common malignant skin lesion. The major aim in the treatment of basal cell carcinoma is the curative treatment, which is best done by Mohs excision of the neoplastic tissue. Despite the effectiveness of surgical excision, non-surgical treatment modalities may be preferred for large tumor size or poor patient performance status. Imiquimod may offer an alternative to surgical excision. Imiquimod is an immune modulator acting as IFN-α and other cytokine inducer, stimulating the innate immune response. Imiquimod's anti-tumor effect may be mediated by IFN-α, IFN-γ, IL-12. At this time, there is no published experience on the treatment of basal cell carcinoma with imiquimod in Korea. We report a case of basal cell carcinoma of the nose successfully treated with topical 5% imiquimod cream.

Original languageEnglish
Pages (from-to)646-649
Number of pages4
JournalKorean Journal of Dermatology
Volume42
Issue number5
Publication statusPublished - 2004 May 1

Fingerprint

imiquimod
Basal Cell Carcinoma
Nose
Therapeutics
Interleukin-12
Korea
Innate Immunity
Neoplasms
Cytokines
Skin

Keywords

  • Basal cell carcinoma
  • Imiquimod

ASJC Scopus subject areas

  • Dermatology

Cite this

A case of basal cell carcinoma of the nose successfully treated with 5% imiquimod cream. / Park, Jun Ha; Hwang, Eul Sang; Kim, Sang Baik; Ahn, Hyo Hyun; Kim, Il-Hwan.

In: Korean Journal of Dermatology, Vol. 42, No. 5, 01.05.2004, p. 646-649.

Research output: Contribution to journalArticle

@article{444ad295b7354fa0bc60589ea1723ac4,
title = "A case of basal cell carcinoma of the nose successfully treated with 5{\%} imiquimod cream",
abstract = "Basal cell carcinoma is the most common malignant skin lesion. The major aim in the treatment of basal cell carcinoma is the curative treatment, which is best done by Mohs excision of the neoplastic tissue. Despite the effectiveness of surgical excision, non-surgical treatment modalities may be preferred for large tumor size or poor patient performance status. Imiquimod may offer an alternative to surgical excision. Imiquimod is an immune modulator acting as IFN-α and other cytokine inducer, stimulating the innate immune response. Imiquimod's anti-tumor effect may be mediated by IFN-α, IFN-γ, IL-12. At this time, there is no published experience on the treatment of basal cell carcinoma with imiquimod in Korea. We report a case of basal cell carcinoma of the nose successfully treated with topical 5{\%} imiquimod cream.",
keywords = "Basal cell carcinoma, Imiquimod",
author = "Park, {Jun Ha} and Hwang, {Eul Sang} and Kim, {Sang Baik} and Ahn, {Hyo Hyun} and Il-Hwan Kim",
year = "2004",
month = "5",
day = "1",
language = "English",
volume = "42",
pages = "646--649",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "5",

}

TY - JOUR

T1 - A case of basal cell carcinoma of the nose successfully treated with 5% imiquimod cream

AU - Park, Jun Ha

AU - Hwang, Eul Sang

AU - Kim, Sang Baik

AU - Ahn, Hyo Hyun

AU - Kim, Il-Hwan

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Basal cell carcinoma is the most common malignant skin lesion. The major aim in the treatment of basal cell carcinoma is the curative treatment, which is best done by Mohs excision of the neoplastic tissue. Despite the effectiveness of surgical excision, non-surgical treatment modalities may be preferred for large tumor size or poor patient performance status. Imiquimod may offer an alternative to surgical excision. Imiquimod is an immune modulator acting as IFN-α and other cytokine inducer, stimulating the innate immune response. Imiquimod's anti-tumor effect may be mediated by IFN-α, IFN-γ, IL-12. At this time, there is no published experience on the treatment of basal cell carcinoma with imiquimod in Korea. We report a case of basal cell carcinoma of the nose successfully treated with topical 5% imiquimod cream.

AB - Basal cell carcinoma is the most common malignant skin lesion. The major aim in the treatment of basal cell carcinoma is the curative treatment, which is best done by Mohs excision of the neoplastic tissue. Despite the effectiveness of surgical excision, non-surgical treatment modalities may be preferred for large tumor size or poor patient performance status. Imiquimod may offer an alternative to surgical excision. Imiquimod is an immune modulator acting as IFN-α and other cytokine inducer, stimulating the innate immune response. Imiquimod's anti-tumor effect may be mediated by IFN-α, IFN-γ, IL-12. At this time, there is no published experience on the treatment of basal cell carcinoma with imiquimod in Korea. We report a case of basal cell carcinoma of the nose successfully treated with topical 5% imiquimod cream.

KW - Basal cell carcinoma

KW - Imiquimod

UR - http://www.scopus.com/inward/record.url?scp=3242723275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242723275&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 646

EP - 649

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 5

ER -